RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 194 participants.
Also called NCT07203521
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 194 participants
- Sponsor
- Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd
- Registry
-
NCT07203521
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07203521. Randomized; single masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2026-04-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
- Condition
- Acute Large Hemispheric Infarction Stroke
- Condition
- Transcranial Bone Marrow Injection
- Condition
- RK-4
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- RK-4 injection
- Intervention (Other)
- conventional treatment
- Lead sponsor
- Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct07203521- Content hash
78b7f1e1ca7e7fa34dd1da453fdb8134f721eab1c363119b564847e956b46d24